ADMP - Adamis Pharmaceuticals Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
Enterprise Value 3
Trailing P/E
Forward P/E 1
PEG Ratio (5 yr expected) 1
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue 3
Enterprise Value/EBITDA 6

Trading Information

Stock Price History

Beta (3Y Monthly) 1.90
52-Week Change 3-81.82%
S&P500 52-Week Change 38.96%
52 Week High 33.2900
52 Week Low 30.4800
50-Day Moving Average 30.6994
200-Day Moving Average 31.2737

Share Statistics

Avg Vol (3 month) 3814.17k
Avg Vol (10 day) 31.11M
Shares Outstanding 561.44M
Float 59.7M
% Held by Insiders 17.21%
% Held by Institutions 117.59%
Shares Short (Sep 30, 2019) 44.11M
Short Ratio (Sep 30, 2019) 44.24
Short % of Float (Sep 30, 2019) 48.76%
Short % of Shares Outstanding (Sep 30, 2019) 46.69%
Shares Short (prior month Aug 30, 2019) 44.37M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 217/1
Last Split Date 3Dec 13, 2013

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin -205.33%
Operating Margin (ttm)-208.27%

Management Effectiveness

Return on Assets (ttm)-56.19%
Return on Equity (ttm)-129.40%

Income Statement

Revenue (ttm)18.66M
Revenue Per Share (ttm)0.41
Quarterly Revenue Growth (yoy)47.00%
Gross Profit (ttm)5.29M
EBITDA -35.85M
Net Income Avi to Common (ttm)-38.31M
Diluted EPS (ttm)-0.8310
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)4.09M
Total Cash Per Share (mrq)0.07
Total Debt (mrq)4.49M
Total Debt/Equity (mrq)13.27
Current Ratio (mrq)1.04
Book Value Per Share (mrq)0.71

Cash Flow Statement

Operating Cash Flow (ttm)-32.95M
Levered Free Cash Flow (ttm)-20.1M